

Intelligently Engineered Skin


Dr Robert Feldman

October 2017

Faster, Bigger, Better

- Vision: to produce the treatment of choice for **large burns** (>30%)
- Growing sheets of patient's own skin to completely cover the burn
- **Faster** delivery - at least twice as quick as all pipeline competition
- **Bigger** sheets than the competition
- **Better** handling and robustness

Current Treatments



- Gold Standard

- Repeated split skin grafts
- For large burns, there is insufficient unburnt skin to graft in one go
- Partial solutions: cadaver skin, dermal fillers and epidermal sheets and sprays




- Upside's Product for

- Payors: ↓hospital stays = ↓costs
- Clinicians: Improved outcome and ease of use
- Patients: Less pain, quicker recovery,

Improved outcome. Possibly less contractures

Multiple Technological Advances


- Cell isolation and culture methods = **speed**
- Biodegradable mesh = **handling**
- Chamber = **size** and **transport**



Intellectual Property

- Six patents protect physical method, mesh characteristics, transport, cell handling and culture methods
- Most advanced at PCT stage

Upside Engineered Skin



Market

- Large burns
 - Orphan Drug and RMAAT designations
 - Easily served market
 - Highly aligned globally
 - Positive feedback from users internationally
 - \$1 billion accessible market

Competitive Pipeline

- Full-thickness allogeneic skin from human cell lines
 - Most likely an effective “dressing”
- Full-thickness autologous skin
 - Delivery too slow and in small pieces
- 3D printing
 - Insufficient cells to print in big burns

Upside's product is the only solution for definitive coverage of a large burn with full thickness skin, delivered

quickly

Hot Field

- 2016: Derma Sciences acquired the regenerative medicine company, BioD in a USD77.8m deal
- 2016: Mallinckrodt plc acquired Stratatech
- 2017: Integra Lifesciences acquired Derma Sciences for >USD204m
- RenovaCare Inc., main technology is preclinical for burns has a market cap of USD237m (OTCMKTS: RCAR; 20 Oct 2017)
- Initial corporate interactions very positive with immediate requests to collaborate

Highlights

- Since incorporation, major milestones broadly on track and company is on budget
- CRADA signed with the US Army Medical Materiel Development Activity and non-dilutive funding from US Military and NZ
- Proof of concept work in mouse model demonstrates engraftment, that the product handles well and does not induce signs of toxicity


CRADA = Cooperative Research and Development Agreement

Structure


- Ords only, simple structure
- Experienced Board
 - David Flacks (chair, NZ)
 - Maxine Simmons (NZ)
 - Will Charles (NZ)
 - Dan Marshak (US)
- Virtual - no employees
- International expert advisors
 - Geoff MacKay (US)
 - Sheila MacNeil (UK)



Rob Feldman, CEO



Rod Dunbar, CSO



Vaughan Feisst, CTO

Financial Information

- Incorporated Nov 2016
- Series A close March 2017, ~\$1.8m
- Shares issued: 5,865,224
- Seeking Capital of \$10m from new investors
- Expect an additional ~\$2m from existing investors

All US Dollars

Use of Funds, Timelines & Exit

- Current funds for definition of product, *in-vivo* PoC and defined regulatory/clinical trial route
- Seeking funds to complete 2 clinical trials
- Q1 2018: readying for phase 1 trial
- Q1 2019: finalise phase 1 trial
- Q2 2020: end of phase 2 trial
- Valuable acquisition target at end of phase 2 trial

A microscopic view of a cell culture, showing numerous cells with red and blue fluorescence. The red fluorescence highlights the cytoplasm and some organelles, while the blue fluorescence highlights the nuclei. The cells are densely packed and exhibit various morphologies, including elongated and rounded forms.

UPSIDE
BIOTECHNOLOGIES

Chamber & GPI Method

- Grow skin cells in flasks
- Transfer to chambers
- Seal chambers
- Incubate
- Invert
- Incubate
- Differentiated skin ready

